Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03159819|
Recruitment Status : Unknown
Verified March 2018 by Bin Wang, Changhai Hospital.
Recruitment status was: Recruiting
First Posted : May 19, 2017
Last Update Posted : March 12, 2018
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Advanced Gastric Adenocarcinoma Pancreatic Adenocarcinoma||Genetic: CAR-CLD18 T Cells||Not Applicable|
For patients with gastric adenocarcinoma who have not been cured with first line chemotherapy, and who are not willing to undergo second line chemotherapy after the failure of first line chemotherapy while there are no effective therapies for their unmet medical needs known at this time, and for patients with advanced/metastatic pancreatic adenocarcinoma which has relapsed after surgery or for which there is no surgical indication, who have not been cured with or refused to receive other standard regimens, single or multiple doses of CAR-CLD18 T cells will be given to observe safety and efficacy of CAR-CLD18 T cells.
Determine the safety, tolerability and cytokinetics of the autologous T cells transduced with anti-Claudin18.2 lentiviral vector in patients with gastric adenocarcinoma and pancreatic adenocarcinoma.
Make a preliminary evaluation on the efficacy of CAR-CLD18 T cells in patients with gastric adenocarcinoma and pancreatic adenocarcinoma with the following parameters:
Time of tumor progression (TTP);
Disease Control Rate (DCR);
Objective Remission Rate (ORR);
Overall Survival (OS).
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Clinical Study of Redirected Autologous T Cells With a Claudin18.2-targeted Chimeric Antigen Receptor in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma|
|Actual Study Start Date :||April 1, 2017|
|Estimated Primary Completion Date :||December 31, 2019|
|Estimated Study Completion Date :||December 31, 2021|
Experimental: CAR-CLD18 T cells
Autologous T Cells with a Claudin18.2-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection.
Lymphodepletion conditioning regimen will be applied prior to CAR-CLD18 T cell infusion.
Genetic: CAR-CLD18 T Cells
Dose escalation will be applied in this study.
Other Name: Claudin18.2-redirected Autologous Cells
- Safety and tolerance [ Time Frame: 24 weeks ]
During the trial conduction, especially within the 24 weeks of treatment phase when CAR-CLD18 T cell administered, all adverse events (including laboratory abnormality and clinical events) will be closely monitored, and all ≥ grade 3 adverse events per CTCAE (v 3.0) will be recorded, including but not limited to the toxicities potentially suspected to relate to infusion procedures and/or CAR-CLD18 T cell therapy as listed below:
- Nausea, vomiting and other gastrointestinal symptoms
- Respiratory distress
- Tumor lysis syndrome
- Cytokine release syndrome
- Neutropenia, thrombocytopenia
- Liver and kidney dysfunction
- Engraftment [ Time Frame: 2 years ]Duration of in vivo survival of CAR-CLD18 T cells is defined as "engraftment". The primary engraftment endpoint is the number of DNA vector copies per mL blood of CAR-CLD18 T cells at regular intervals through week 4 following the initial infusion. Q-PCR for CAR-CLD18 T vector sequences will be performed until any 2 sequential tests are negative, documented as engraftment and persistence of CAR-CLD18 T cells.
- Anti-tumor responses to CAR-CLD18 T cell infusions [ Time Frame: 2 years ]Disease Control Rate (DCR)
- Anti-tumor responses to CAR-CLD18 T cell infusions [ Time Frame: 2 years ]Progression-free Survival (PFS)
- Anti-tumor responses to CAR-CLD18 T cell infusions [ Time Frame: 2 years ]Time of Tumor Progression (TTP)
- Anti-tumor responses to CAR-CLD18 T cell infusions [ Time Frame: 2 years ]Overall Survival (OS)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 70 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients aged 18 - 70 with pathologically confirmed advanced gastric adenocarcinoma and pancreatic adenocarcinoma.
- Biopsy confirmation of Claudin18.2 positive.
- Patients with advanced gastric adenocarcinoma who have not been cured with second line chemotherapy, and who are not willing to undergo second line chemotherapy after the failure of first line chemotherapy. (1) Failure of treatment is defined as disease progression, recurrence or metastatic disease, or intolerable toxicities occurred after treatment. (2) Each line of treatment during the period of disease progression includes one or more chemotherapy drugs which are administered for not less than one cycle or even longer. Neoadjuvant/adjuvant therapy can be applied at an earlier stage of treatment. If patient has developed recurrence or metastatic disease within 24 weeks of neoadjuvant/adjuvant therapy, it is considered as one line of systemic chemotherapy. (3) Therapies that can be performed at an earlier stage are chemotherapy in conjunction with molecular targeted drugs.
- Patients with advanced/metastatic pancreatic adenocarcinoma which has relapsed after surgery or for which there is no surgical indication, who have not been cured with or refused to receive other standard regimens.
- Expected survival after first dose of study drug > 12 weeks.
- At least one measurable lesion (≥ 10 mm) for imaging assessment.
- ECOG scores 0 - 1.
- Adequate venous access for apheresis and venous blood sampling, and no other contraindications for leukapheresis.
- White blood cells (WBCs) ≥ 2.5×10^9/L Platelets (PLT) ≥ 100×10^9/L Hemoglobin, Blood (Hb) ≥ 9.0 g/dL MID ≥ 1.5×10^9/L Lymphocyte (LY) ≥ 0.47×10^9/L LY% ≥ 15%
- Serum albumin (Alb) ≥ 30 g/L
- Serum lipase (LPS) and serum amylase < 1.5 ULN
- Serum creatinine ≤ 1.5 ULN
- Alanine aminotransferase (ALT) ≤ 2.5 ULN Aspartate aminotransferase (AST) ≤ 2.5 ULN If osseous metastasis or liver metastasis is developed and alkaline phosphatase (ALP) > 2.5 ULN, ALT and AST < 1.5 ULN.
- Serum total bilirubin (TBIL) ≤ 1.5 ULN
- Prothrombin Time (PT): International Normalized Ratio (INR) < 1.7. PT < (ULN + 4) s
All test results should be within their normal ranges, and the patient is not receiving continuous supportive care.
Patients with any of the following conditions are not eligible for the study.
- Pregnant or lactating women.
- HIV positive, HCV positive, HBV DNA copies ≥ 10^3.
- Uncontrolled active infection.
- Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
- Allergic to immunotherapies and related drugs.
- Untreated brain metastases or having symptoms of brain metastases.
- Metastases to the lung: central tumor or multiple metastases.
- Patients with heart disease for which treatment is needed or with poorly controlled hypertension.
- Patients with unstable or active peptic ulcer or with alimentary tract hemorrhage.
- Patients with previous organ transplantation or in preparation for organ transplantation.
- Patients in need of anticoagulant treatment (e.g. warfarin or heparin).
- Patients in need of long-term antiplatelet treatment (aspirin, dosage > 300 mg/d; clopidogrel, dosage > 75 mg/d).
- Previous treatment with chemoradiotherapy and tumor-targeting drug which were conducted 4 weeks prior to the study (blood collection).
- Patients have undertaken major surgeries or have been badly injured 4 weeks before the study (blood collection), or will undertake major surgeries during the study.
- The judgment of investigators that the patient is not able to or not willing to follow the instructions of the protocol.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03159819
|Contact: Xianbao Zhan, M.D.||email@example.com|
|Shanghai, Shanghai, China, 200433|
|Contact: Bin Wang, Dr. 86-021-31161448 firstname.lastname@example.org|
|Principal Investigator: Xianbao Zhan, M.D.|
|Sub-Investigator: Bin Wang, M.D.|
|Principal Investigator:||Xianbao Zhan, M.D.||Changhai Hospital|
|Responsible Party:||Bin Wang, Attending physician, Changhai Hospital|
|Other Study ID Numbers:||
|First Posted:||May 19, 2017 Key Record Dates|
|Last Update Posted:||March 12, 2018|
|Last Verified:||March 2018|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type